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The lateral division of the central amygdala
(CeAL) is the target of ascending fibers from
the pain-responsive and stress-responsive nu-
clei in the brainstem. We show that single fiber
inputs from the nociceptive pontine parabrachial
nucleusontoCeALneurons form suprathreshold
glutamatergic synapses with multiple release
sites. Noradrenaline, acting at presynaptic a2
receptors, potently inhibits this synapse. This
inhibition results from a decrease in the number
of active release sites with no change in release
probability. Introduction of a presynaptic scav-
enger of Gbg subunits blocked the effects of
noradrenaline, and botulinum toxin A reduced
its effects, showing a direct action ofbg subunits
on the release machinery. These data illustrate
a mechanism of presynaptic modulation where
the output of a large multiple-release-site syn-
apse is potently regulated by endogenously
released noradrenaline and suggests that the
CeA may be a target for the central nociceptive
actions of noradrenaline.
INTRODUCTION
The amygdala is a subcortical structure that plays a key
role in attaching emotional significance to sensory stimuli.
Pain is a complex experience that includes the subjective
experience of the pain as well as the emotional and cogni-
tive response to it. The central nucleus of the amygdala
(CeA), which forms the output nucleus of the amygdaloid
complex (Sah et al., 2003), receives direct nociceptive in-
puts from trigeminal and spinal sources via the pontine
parabrachial nucleus (PB), an anatomical organization
that has been described as the ‘‘nociceptive amygdala’’
(Neugebauer et al., 2004). In turn, the CeA has projections
to hypothalamic and brainstem regions that regulate
physiological responses as well as extensive projections
to cortical areas that initiate affective responses (Davis
and Whalen, 2001; LeDoux, 2000; Sah et al., 2003). The
presence of direct nociceptive inputs to the CeA, coupled
with its role in emotional processing, makes this region880 Neuron 56, 880–892, December 6, 2007 ª2007 Elsevier Incwell positioned to integrate nociceptive activity with emo-
tional arousal. Thus, pain states are well known to have
significant negative affective value, and chronic pain can
ultimately lead to anxiety and depression (Craig, 2006),
both of which are recognized to involve the amygdala
(Davis and Whalen, 2001).
The noradrenergic system arises from cell groups in the
brainstem that have projections to the spinal cord (Fields
et al., 2006; Yoshimura and Furue, 2006), as well as as-
cending projections that target almost the entire forebrain
(Bouret and Sara, 2005). Visceral activation of these cell
groups results in major effects on the response to pain
(Jones, 1991). The nociceptive actions of noradrenaline
from its actions on afferent activity as it enters the spinal
cord are well known (Fields et al., 2006; Yoshimura and
Furue, 2006). However, noradrenaline also has cognitive
and behavioral actions due to its supraspinal actions
(Berntson et al., 2003; Yaksh, 2006). While exogenously
applied noradrenaline has a range of actions on central
neurons (Nicoll et al., 1990), its actions in modulating par-
ticular sensory inputs are not well understood. The CeA
receives a particularly dense ascending noradrenergic
projection (Fallon et al., 1978; Riche et al., 1990; Zardetto-
Smith and Gray, 1995) and has a high level of a2A adreno-
ceptor expression (Talley et al., 1996). Given the presence
of a strong nociceptive input into the CeA, it is likely that
the affective actions of noradrenergic stimulation may re-
sult from a supraspinal action on nociceptive inputs to the
amygdaloid complex. In agreement with this, monoamine
uptake blockers that have been widely used as analgesics
(Sindrup et al., 2005) are particularly effective when deliv-
ered into the cerebral ventricles, indicating a supraspinal
mode of action (Sawynok et al., 2001). However, the
cellular mechanisms that may underlie these supraspinal
actions of noradrenaline are not known.
Recent anatomical data have revealed that fibers
projecting from the PB to the lateral division of the central
amygdala (CeAL) targeted single neurons in the CeA, ter-
minating in perisomatic basket terminals (Sarhan et al.,
2005). Here we show that these terminals form large ex-
citatory synapses with multiple release sites that are po-
tently inhibited by synaptically released noradrenaline.
This inhibition results from presynaptic activation of a2
adrenoceptors that reduces synaptic transmission by
blocking some release sites by an action that is mediated
by G protein bg subunits and is downstream of
calcium influx. These findings show that noradrenergic.
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Noradrenergic Inhibition in the Central AmygdalaFigure 1. Parabrachial Neurons Project to the Lateral and
Lateral Capsular Divisions of Central Amygdala and Form
Somatic Synapses
(A) DiI injection site in the lateral parabrachial nucleus.
(B) Low-magnification (43) bright-field image of themedial (CeAM) and
lateral divisions (CeAL) of central amygdala.
(C) Fluorescence image of the slice shown in (B), showing DiI-positive
labeling in the lateral division.
(D) DiI-positive fibers entering the CeA via the medial VAF pathway
(denoted with an asterisk to indicate positioning of bipolar stimulator
in subsequent experiments).
(E) Fluorescence image of DiI-positive terminals in the CeAL (203
magnification), showing a high density of cells contacted by these
terminals in the CeAL.Nestimulation modulates transmission of nociceptive infor-
mation into the amygdala by a presynaptic mechanism.
RESULTS
The parabrachial (PB) nucleus sends a large projection to
the central amygdala, with axons terminating in both its
capsular (CeAC) and the lateral (CeAL) division (Sarhan
et al., 2005). We first identified the course of these axons
in coronal brain slices by injecting the tracer DiI into the
PB (Figure 1A). DiI injection resulted in extensive labeling
of terminals in the CeAL (Figures 1B and 1C) and revealed
that projections from PB neurons travel along the ventral
amygdaloid fiber tract (VAF, asterisk in Figure 1D) and
course around the dorsal extent of the optic tract before
entering the CeA via the stria terminalis. On entering the
CeA, individual PB axons form large perisomatic basket-
like terminations around the somata of CeAL neurons (Fig-
ure 1) (Sarhan et al., 2005).
Noradrenaline Inhibits Parabrachial Excitatory
Input to the Central Amygdala
To examine the properties of PB inputs to CeAL neurons,
whole-cell recordings were made from neurons in the
CeAL that were targeted by DiI-positive PB terminals
(Figures 2A and 2B). PB afferents were activated using
minimal stimulation (Raastad et al., 1992) within the VAF
bundle to activate single fiber inputs (Figures 1D and
2A). At a holding potential of 60 mV, stimulation of PB
afferents evoked a large (122.1 ± 14.0 pA, n = 14) excit-
atory postsynaptic current (EPSC). This response was all
or none, and increasing the stimulation strength did not
change its amplitude (Figure 2C), consistent with activa-
tion of perisomatic basket terminals originating from a sin-
gle axon (Sarhan et al., 2005). Notably, the evoked EPSC
was significantly larger (p < 0.01, n = 6 cells) thanminiature
asynchronous synaptic events recorded from the same
terminals (Figure 5; 13.6 ± 2.6 pA, n = 6), indicating that
activation of these single fiber inputs results in transmitter
release from multiple release sites. Recording in current
clamp using potassium-based internal solutions and min-
imal stimulation resulted in a large, fast-rising evoked
postsynaptic potential (EPSP) (Figure 2D, average ampli-
tude 9.1 ± 1.5 mV, n = 8 cells) that was sufficient to drive
CeAL cells to threshold in most cases (7 out of 8 cells
recorded). Both the EPSP and the evoked inward current
were completely abolished by the AMPA/kainate receptor
(F) High-magnification (403) confocal fluorescence image of single
DiI-positive perisomatic basket terminals in the CeAL.
(G) Composite Z-stack confocal image of the terminal shown in top
right of (F).
Scale bars, (A–D) 200 mm, (E) 50 mm, (F and G) 5 mm. Axes: D, dorsal; L,
lateral; LC, locus coeruleus; LPBC, lateral parabrachial nucleus central
part; LPBV, lateral parabrachial nucleus ventral part; LPBE, lateral par-
abrachial nucleus external part; MPB, medial parabrachial nucleus;
vsc, ventral spinocerebellar tract; scp, superior cerebellar peduncle;
4V, fourth ventricle.uron 56, 880–892, December 6, 2007 ª2007 Elsevier Inc. 881
Neuron
Noradrenergic Inhibition in the Central AmygdalaFigure 2. The Parabrachial Nucleus Provides Strong Excit-
atory Input to the Lateral Division of Central Amygdala
(A) Recording configuration for recording evoked PB-CeAL synaptic
responses. Axis: D, dorsal; M, medial.
(B) Fluorescence (left) and DIC (right) image of CeAL cell targeted by
DiI-positive PB basket terminal (scale bars, 10 mm).
(C) Stimulus-response curve for stimulation of PB afferents. Low stim-
ulus intensity fails to evoke a response (traces on left). Supratheshold
stimulation evokes all or none responses that do not increase with
higher intensity stimulation (traces on right).
(D) Fluorescence images (left) showing basal signal from magnesium
green-loaded PB terminals (top left) colocalizing with DiI labeling (bot-
tom left) and electrically stimulated calcium transients (right) in control,
unaffected by NBQX (10 mM) and d-APV (30 mM) and blocked by TTX
(1 mM).
(E) EPSPs resulting from single fiber PB input stimulation are large and
frequently drive the CeAL cells to threshold.
(F) Application of NBQX (5 mM) blocks the EPSP, showing it is glutama-
tergic.
CeAC, lateral capsular division of central amygdala; CeAL, lateral divi-
sion of central amygdala; CeAM, medial division of central amygdala;
LA, lateral amygdala; BLA, basolateral amygdala. GABA receptors
have been blocked with 100 mM picrotoxin and 3 mM CGP55845A.882 Neuron 56, 880–892, December 6, 2007 ª2007 Elsevier Incantagonist NBQX (Figure 2E, n = 3), showing that gluta-
mate is the transmitter at these synapses.
To confirm that minimal stimulation in the VAF pathway
activated basket synapses in theCeA that originated in the
PB, we loaded a low-affinity calcium indicator, magne-
sium green, into the basket terminal (see Experimental
Procedures) to image action potential-driven presynaptic
calcium influx in the PB terminals. Terminals loaded with
indicator could be clearly seen as baskets in the CeAL,
similar to those revealed by injection of DiI into the PB (Fig-
ure 1). Electrical stimulation of the VAF pathway evoked
transient rises in calcium in these basket terminals (Fig-
ure 2F). These calcium rises were insensitive to the gluta-
mate receptor antagonists NBQX and d-APV (10 mM and
30 mM, respectively, n = 2) but were blocked by the so-
dium channel blocker tetrodotoxin (1 mM, n = 2), confirm-
ing that the recorded calcium signals were action potential
driven.
These results show that single fiber PB afferents to neu-
rons in the CeAL form large synapses that can drive these
neurons to threshold. Application of noradrenaline (10 mM)
caused rapid and reversible inhibition of the PB input
(Figure 3A), arresting synaptically induced firing (4/4 cells),
and reduced the size of the evoked EPSP by 63.2% ±
4.7% (using subthreshold EPSPs for control, p < 0.01, n = 4).
These effects of noradrenaline were reversed by the
selective a2-adrenoceptor antagonist yohimbine, restor-
ing synaptically evoked firing in 3/3 neurons (20 mM,
Figure 3A), and were not due to modulation of the proper-
ties of the postsynaptic neuron, as action potentials
evoked by a brief depolarizing current injection were unaf-
fected by noradrenaline (Figure 3A).
To further pharmacologically characterize the effects
of noradrenaline, we examined its actions on excitatory
postsynaptic currents (EPSCs). Stimulating electrodes
were placed in the VAF pathway and the basolateral
amygdala (BLA input) to activate two independent inputs
to CeAL neurons (Lopez de Armentia and Sah, 2004). Ap-
plication of noradrenaline (10 mM) resulted in a rapid and
reversible inhibition of the PB-EPSC of 70.9% ± 3.7%
(n = 21, p < 0.01), with no effect on the BLA-EPSC (Fig-
ure 3B; 1.1% ± 10.9%, n = 8, p > 0.44). This effect of nor-
adrenaline was dose dependent, reaching maximal effect
at 100 mM, and the dose-response curve was well fitted
with a Hill equation with an EC50 of 2.3 mM (Figure 3C).
The specific a2-adrenoceptor antagonist yohimbine
(20 mM) blocked noradrenergic inhibition of the PB input
(Figures 3D and 3E: 8.9% ± 3.0% p > 0.05, n = 7), whereas
the selective a1-adrenoceptor antagonist prazosin had no
effect (Figure 3E: 58.8% ± 8.3% inhibition, p < 0.05, n = 5).
Furthermore, the a2-subtype-selective adrenoceptor ago-
nist clonidine (20 mM) both inhibited the PB input (75.8% ±
2.8%, n = 5, p < 0.05) and occluded the effect of subse-
quently applied noradrenaline (9.5% ± 10.0% inhibition,
n = 4, p = 0.42, data not shown). a1- and b-adrenocep-
tor-selective agonists (cirazoline and isoprenaline) had
no significant effect on the PB input (4.1% ± 1.2% facilita-
tion and 10.2% ± 14.1% inhibition, respectively, n = 4 for.
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Noradrenergic Inhibition in the Central AmygdalaFigure 3. Noradrenaline Inhibits PB-CeA
Synapses and Arrests Synaptically In-
duced Firing
(Ai) Electrically evoked PB-CeAL input drives
the CeAL cell to fire action potentials (top) in
control conditions, but not in the presence of
10 mM noradrenaline (NAd). Addition of yohim-
bine (yoh, 20 mM) blocks the noradrenergic
inhibition of firing. Control action potentials
driven by brief depolarizing current injections
(500 pA, 2 ms, lower trace) are unaffected by
noradrenaline or yohimbine.
(Aii) Individual synaptic and current injection
responses in control and in noradrenaline. Nor-
adrenaline inhibits firing by reducing the size of
the evoked EPSP to subthreshold range.
(B) Excitatory synaptic currents were evoked
by alternatively stimulating parabrachial (PB)
and basolateral nucleus (BLA). Normalized
EPSC amplitude is plotted for PB-CeAL (filled
circles) and BLA-CeAL input (open squares)
onto one CeAL cell, showing noradrenaline in-
hibition of the PB input (average traces shown
under in control and noradrenaline) but not the
BLA input (averages shown under).
(C) Noradrenaline dose/inhibition curve for the
noradrenaline inhibition of the PB input.
(D) Plot of normalized PB-CeA EPSC amplitude
showing reversible noradrenaline inhibition.
Yohimbine blocks this effect (averages in
each condition shown below).
(E) Summary data showing the percent inhibi-
tion of 10 mM noradrenaline on BLA inputs
(unfilled column) and on PB inputs in control,
20 mM yohimbine, and 10 mM prazosin (filled
columns left to right, respectively, p < 0.01,
n = 8, 21, 7, and 5, respectively). GABA recep-
tors have been blocked with 100 mMpicrotoxin
and 3 mM CGP55845A.
Error bars show ± SEM.each, data not shown). Thus, noradrenaline effectively
reduces synaptic transmission at parabrachial inputs to
CeAL neurons by activating a2 adrenoceptors.
Noradrenaline Acts Presynaptically at PB-CeAL
Synapses
Noradrenergic block of the PB-evoked EPSC could either
be due to a change in transmitter release or due to modu-
lation of postsynaptic receptors. To determine whether
noradrenaline modulates the postsynaptic AMPA recep-
tor pool, we examined spontaneous excitatory postsyn-
aptic currents (sEPSC, isolated in 100 mM picrotoxin) re-
corded in voltage clamp at a holding potential of 60 mV.
Neither the amplitude nor the frequency of sEPSCs
(Figure 4A) was significantly changed from control by nor-
adrenaline (4.4% ± 3.4% decrease and 5.7% ± 8.2%
decrease, respectively, p > 0.05, n = 16). Miniature EPSCs
recorded in the presence of tetrodotoxin (data not shown)
showed similar insensitivity to noradrenaline (7.7% ±
6.9% decrease in amplitude and 3.6% ± 6.4% increase
in frequency, p > 0.05 for both, n = 6). These results sug-Ngest that the postsynaptic AMPA receptors are not altered
by noradrenaline. However, CeAL neurons receive inputs
from a variety of different sources, some of which are in-
sensitive to noradrenaline (e.g., Figure 3B). Thus, it is con-
ceivable that the majority of the spontaneous events we
have measured are from inputs that are not affected by
noradrenaline. To isolate unitary synaptic responses aris-
ing fromPB inputs, we recorded asynchronous evoked re-
lease events by replacing extracellular calcium with 5 mM
strontium (Goda and Stevens, 1994) and activated single
PB afferents as before (Figure 4B). The amplitude of these
events (occurring between 20 ms and 120 ms poststimu-
lus to exclude synchronously released evoked events)
was not changed by addition of 10 mM noradrenaline
(7.3% ± 12.3%, Figures 4B and 4C), indicating that norad-
renergic stimulation does not modulate postsynaptic
AMPA receptors. However, the frequency of strontium-
evoked asynchronous events occurring in this delayed
time window was reduced by noradrenaline (43.1% ±
4.5%, n = 6, p < 0.01), suggesting a presynaptic locus for
the effect of noradrenaline at this synapse.euron 56, 880–892, December 6, 2007 ª2007 Elsevier Inc. 883
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Noradrenergic Inhibition in the Central AmygdalaFigure 4. Spontaneous EPSC and Asyn-
chronous Unitary PB EPSC Amplitudes
Are Unaffected by Noradrenaline
(A) Traces showing spontaneous EPSCs
(sEPSCs) recorded from a CeAL cell in control
and in 10 mM noradrenaline. Average sEPSC
from each condition are shown superimposed
on the right.
(B) Traces showing evoked PB-CeAL EPSCs
recorded in control Ringer (2.5 mM calcium),
in strontium Ringer (4 mM Sr2+, 0 mM calcium;
labeled Sr2+), and in strontium Ringer following
application of 10 mM noradrenaline (Sr2+ +
NAd). (Inset) Average unitary EPSCs collected
from the 100 ms period commencing at 25 ms
poststimulus, in strontium alone and in stron-
tium and noradrenaline.
(C) Summary data showing effect of 10 mMnor-
adrenaline on the amplitude (filled columns)
and frequency (unfilled columns) of spontane-
ous EPSCs (sEPSC), miniature spontaneous
EPSCs (mEPSC; collected in 1 mM tetrodotoxin
to block action potential-driven events), and
evoked asynchronous unitary PB-CeAL
EPSCs (Sr mEPSC) recorded from CeAL cells
(n = 16, 6 and 6 cells, respectively).
Error bars show ± SEM.Glutamatergic synapses on CeAL neurons are typical
dual-component synapses that express both AMPA and
NMDA receptors (Lopez de Armentia and Sah, 2003). If
the adrenergic inhibition is mediated by a presynaptic
mechanism, then evoked EPSCs mediated by NMDA re-
ceptors should be similarly inhibited by noradrenaline.
We therefore recorded evoked NMDA receptor-mediated
EPSCs at +40 mV by electrical stimulation of PB inputs.
Noradrenaline reduced the NMDA receptor-mediated
EPSC to a similar extent as the AMPA receptor-mediated
EPSC recorded at60 mV (72.1% ± 8.2% inhibition mea-
sured 50 ms poststimulation, p < 0.05, n = 4, Figure 5A).
This result is consistent with a presynaptic action of nor-
adrenaline, as it is unlikely that postsynaptic modulation
by noradrenaline would affect both receptor types equally.
We next investigated whether noradrenaline reduces
synaptic efficacy by modulating transmitter release prob-
ability. To monitor release probability, we measured the
ratio of the postsynaptic response to two stimuli delivered
at an interval of 50 ms, the paired-pulse ratio (PPR)
(Zucker, 1989). Application of noradrenaline resulted in
a similar block in the amplitude of both EPSCs with no sig-
nificant change in PPR (Figure 5B; 1.35 ± 0.05 in control
and 1.41 ± 0.08 in noradrenaline, n = 26, p = 0.27). In con-
trast, lowering extracellular calcium to 0.5 mM (Figure 5C)
or activating presynaptic GABAB receptors using the se-
lective agonist baclofen (2 mM; Figure 5D), manipulations
that reduce release probability, both reduced PB-CeAL
EPSCs to a similar degree as that achieved by 10 mM nor-
adrenaline (58.2% ± 5.2% and 57.3% ± 4.9%, respec-
tively) but were also accompanied by clear increases in
PPR (Figure 5E; from 1.35 ± 0.09 to 1.68 ± 0.07 for low cal-
cium and 1.30 ± 0.06 to 1.63 ± 0.12 for baclofen, n = 12
and 10, p < 0.01). Together with the reduction in frequency884 Neuron 56, 880–892, December 6, 2007 ª2007 Elsevier Inof asynchronous events evoked in strontium (Figure 4B),
these results show that noradrenaline reduces transmitter
release at PB inputs by a presynaptic mechanism that
does not change release probability.
Noradrenaline Reduces the Number
of Presynaptic Release Sites
At synapses with a number of release sites (N) with an
average release probability p, the response of the post-
synaptic neuron is given by N 3 p 3 q, where q is the
response to release of a quantum of transmitter at one re-
lease site (Katz and Miledi, 1972). We have shown that
reduction of the EPSC at PB inputs is not due to a change
in the amplitude of miniature EPSCs (q) or the release
probability (p). To test whether noradrenaline could
change N, we used variance mean analysis (Clements,
2003) (see Experimental Procedures). Variance-mean
curves for PB-CeAL EPSCs stimulated in control condi-
tions and in the presence of 10 mM noradrenaline were
generated for a range of release probabilities by altering
the calcium:magnesium ratios in the perfusing solution
(Figure 6). The average variance and mean across cells
for each external calcium/magnesium concentration in
control or in noradrenaline (n = 8) were fitted with parabolic
functions (see Experimental Procedures). On visual in-
spection, the shape of these curves is consistent with nor-
adrenaline producing a change in the number of release
sites with no change in release probability (Clements,
2003; Foster and Regehr, 2004). This analysis indicates
that the lower limit to the number of release sites (NT)
was 17 in the control condition, whereas application of
noradrenaline reduced it to 7 (a 59% reduction in release
sites). The derived quantal current amplitude (q) in control
and noradrenaline were similar (12.1 pA and 11.8 pA,c.
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Noradrenergic Inhibition in the Central AmygdalaFigure 5. Noradrenaline Reduces Both
Components of the EPSC but Does Not
Alter Paired-Pulse Ratio
(A) Average evoked PB-CeAL EPSCs are
shown in control and in the presence of nor-
adrenaline (10 mM) recorded at holding poten-
tials of 60 mV (Ai) and +40 mV (Aii). GABA
receptors have been blocked with 100 mM
picrotoxin and 3 mM CGP55845A.
(B) Plot of evoked PB-CeAL amplitude for
paired stimuli (50 ms interstimulus interval;
stim 1, filled squares; stim 2, unfilled squares)
and PPR for each paired stimulation (filled
circles) during the application of 10 mM nor-
adrenaline. Average traces from control and
noradrenaline (Bi) and normalized and overlaid
(Bii).
In contrast to noradrenaline, reduction of exter-
nal calcium concentration to 0.5 mM (C) or ap-
plication of 2 mM baclofen to activate GABAB
receptors (D) reduces the PB-CeAL EPSC
with a clear change in paired-pulse ratio (aver-
age PPR in each condition shown in [E]).
Traces have been normalized and overlaid as
in (Bii).
Error bars show ± SEM.respectively) and close to the amplitude of quantal events
evoked in strontium (Figure 4B; mEPSC amplitude 13.6
pA, n = 6 cells). Moreover, at 2.5 mM Ca2+, the estimated
release probability was 0.46 under control conditions and
0.48 in 10 mM noradrenaline. These results show that
noradrenaline acts to reduce the number of release sites
without affecting the quantal size or release probability.
Noradrenergic Modulation Is Independent
of Presynaptic Calcium Influx
We have shown that noradrenaline acting at a2 adreno-
ceptors reduced transmitter release at parabrachial inputs
by a mechanism that did not involve a reduction in release
probability. Instead, variance-mean analysis suggests
that noradrenaline reduces the number of active release
sites. a2 adrenoceptors are thought to be coupled to per-
tussis toxin-sensitive Gi/o type G proteins (Hein, 2006),Nand we next tested the downstream effector mechanisms
activated. Uncoupling petussis toxin-sensitive G proteins
with either pertussis toxin (4 hr incubationat 34C in 5mg/ml)
or the sulphydryl alkylating agent N-ethylmaleimide (NEM,
bath applied for 15 min at 250 mM) (Hoshino et al., 1990)
blocked noradrenergic inhibition (Figure 7A; NEM,
6.4% ± 3.2% inhibition; PTX, 9.6% ± 16.1% inhibition;
p > 0.05, n = 4 and 3, respectively), indicating that Gi/o ac-
tivation was required. To confirm that the effects of nor-
adrenaline were mediated by presynaptic receptor activa-
tion, we replaced the GTP in our internal solution with its
nonhydrolysable analog (GTPgS; 0.3 mM). As expected,
in neurons postsynaptically loaded with GTPgS, the post-
synaptic effects of the GABAB agonist baclofen were fully
blocked (n = 4, data not shown); however, PB-CeAL
EPSCs remained sensitive to noradrenaline (Figure 7A;
61.5% ± 7.4% inhibition, p < 0.05, n = 4), consistenteuron 56, 880–892, December 6, 2007 ª2007 Elsevier Inc. 885
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Noradrenergic Inhibition in the Central Amygdalawith a presynaptic action of noradrenaline. To test
whether the actions of noradrenaline were mediated by
Gbg subunits, we next applied the membrane-permeant
Gbg-binding peptide mSIRK (Chen et al., 2005). We found
that direct application of mSIRK to the presynaptic termi-
nals by low-pressure application (20 mM, 10–15 min)
blocked the effect of noradrenaline (Figure 7A; pre/post
mSIRK, 2.9% ± 11.9% inhibition; n = 5, p = 0.4). In
contrast, loading mSIRK into the postsynaptic neuron
had no effect (Figure 7A; EPSC amplitude post mSIRK,
72.5 ± 5.6 inhibition, p < 0.01, n = 4). Thus, noradrenergic
modulation of transmitter release at these PB-CeAL syn-
apses requires activation of presynaptic Gi/o proteins
and is mediated by Gbg signaling.
Inhibition of transmitter release by activation of presyn-
aptic G protein-coupled receptors has been demon-
strated for many neurotransmitters (including noradrena-
Figure 6. Variance-Mean Analysis Indicates that Noradrena-
line Reduces the Number of Release Sites Contributing to
the Evoked PB-CeA EPSC
(A) Plot of individual evoked PB-CeAL EPSC amplitude for events stim-
ulated in 0.5–4.5 mM external calcium in control (Ai) and in 10 mM
noradrenaline (Aii).
(B) Plot of the variance of individual EPSCs at each external calcium
concentration versus the average amplitude of these events, in control
(filled circles) and in 10 mMnoradrenaline (unfilled circles) for the exam-
ple shown in (A).
(C) Average variance-mean curve for PB-CeAL EPSCs recorded in
control (filled circles, 0.5–4.5 mM external calcium, n = 8 cells) and in
10 mM noradrenaline (unfilled circles, 0.5–4.5 mM external calcium,
n = 8 cells). Data points have been fit with a parabola (see Experimental
Procedures) with the indicated values.
All error bars show ± SEM.886 Neuron 56, 880–892, December 6, 2007 ª2007 Elsevier Incline), where the presynaptic actions of these receptors
are mediated by released Gbg subunits that act either
on voltage-dependent calcium channels or potassium
channels, both of which effectively reduce calcium influx
and reduce transmitter release (Chieng and Bekkers,
1999; Miller, 1998). This inhibition is selective for particular
subtypes of calcium channel (Chieng and Bekkers, 1999;
Dolezal et al., 1996). Thus, while we do not see a change in
release probability, it is conceivable that a site-specific
inhibition of these multi-release-site terminals by nor-
adrenaline is due to differential expression of VGCCs and
a2-adrenoceptors at individual release sites. If this were
the case, then the inhibition of calcium influx at a subset
of sites containing both the a2-adrenoceptor and the ap-
propriate VGCC would reduce release from these sites
only. To test whether presynaptic calcium influx is re-
duced by noradrenaline, we loaded PB basket terminals
with the low-affinity fluorescent calcium indicator magne-
sium green (Figure 2). Application of noradrenaline had no
effect on action potential-driven calcium influx into the PB
terminals (10 mM, Figure 7B). In contrast, calcium influx
was significantly reduced by the GABAB agonist baclofen
(1 mM, Figure 7B) (Isaacson, 1998) and completely
blocked by the VGCC blocker cadmium (50 mM, Fig-
ure 7B). These experiments demonstrate that there is no
change in the action potential-driven rise in terminal free
calcium across the entire terminal, showing that noradren-
aline acts downstream of calcium influx. How then does
noradrenaline reduce transmitter release?
G protein receptor-mediated effects on transmitter re-
lease downstream of calcium influx have also been previ-
ously proposed (Blackmer et al., 2001; Chen et al., 2005;
Dittman and Regehr, 1996; Miller, 1998; Nicola and Mal-
enka, 1997; Scanziani et al., 1992). Moreover, recent stud-
ies have found that at lamprey giant reticuospinal termi-
nals these actions are mediated by Gbg subunits that
inhibit vesicular release (Blackmer et al., 2005; Gerach-
shenko et al., 2005) by binding to the C terminus of
SNAP-25 (Blackmer et al., 2005), a key component of
the SNARE complex (Gerachshenko et al., 2005). To test
whether noradrenergic modulation at PB-CeAL synapses
was similarly mediated by Gbg interaction with the release
machinery, we incubated slices in botulinum toxin A
(BoNT A, 0.2 nM), which cleaves the Gbg binding site on
the SNAP-25 (Blackmer et al., 2005), and tested the effect
of noradrenaline. Incubation of slices in BoNT reduced the
amplitude of the evoked EPSC (Figure 7C) and, consistent
with previous studies (Gerachshenko et al., 2005), norad-
renergic inhibition was reduced with increasing incubation
time in BoNT (Figure 7C), showing that the reduced avail-
ability of functional Gbg interaction sites on SNAP-25 re-
duces the effect of noradrenaline at PB-CeAL synapses.
As noradrenergic modulation appears to interact with
the vesicular release machinery directly, it is possible
that activation of a2 receptors could also affect docking
of new vesicles to presynaptic active zones. If vesicles
were prevented from docking, then presumably those re-
lease sites would become silent through activity-driven.
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Noradrenergic Inhibition in the Central AmygdalaFigure 7. Noradrenergic Inhibition Re-
quires Presynaptic Gi/o Activity but
Does Not Reduce Presynaptic Calcium
Influx
(A) Histogram showing the noradrenergic
(10 mM) inhibition of evoked PB-CeAL EPSC re-
corded in control conditions, following bath
application of N-ethylmaleimide (NEM), incu-
bation in pertussis toxin (PTX), with internal
GTP replaced by GTPgS (GTPgS), following
low-pressure application of mSIRK to the
pre- and postsynaptic cell (pre/post mSIRK),
and with mSIRK loaded into the postsynaptic
cell (post mSIRK) (n = 21, 4, 3, 4, 4, 5, and 4,
respectively, **p < 0.01, *p < 0.05).
(B) Electrically stimulatedcalcium transients im-
aged fromMagnesiumgreen-filledPB terminals
(see Figure 2) in control (filled diamonds), unaf-
fected by exogenously applied noradrenaline
(10 mM; unfilled squares), partially blocked by
the GABAB receptor agonist baclofen (2 mM;
filled circles), and completely blocked by the
nonselective voltage-gated calcium channel
(VGCC) blocker cadmium (50 mM; unfilled trian-
gles). (Right) Summaryof theeffect of noradren-
aline (10 mM) and baclofen (2 mM) on action
potential-driven calcium entry into PB basket
terminals (measured as the area under the cal-
cium transient, n = 5 and 4, respectively).
(C) Increasing incubation of slices in botulinum
toxin A (0.2 nM) reduces the amplitude of
evoked PB-CeAL EPSC (unfilled circles) and
the inhibitory effects of noradrenaline (10 mM;
filled squares). Repeated-measures two-way
ANOVA shows a significant interaction be-
tween the effects of noradrenaline and BoNT
A (p = 0.017).
(D) Time course plot showing control EPSC
amplitude (0–6 min), prior to cessation of stim-
ulation and application of 10 mMnoradrenaline for 8 min. On stimulation recommencing in the presence of noradrenaline, maximal inhibition has been
reached. Average responses in control and noradrenaline shown on right.
(E) Recovery of synaptic transmission in noradrenaline is slow. Paired PB-CeAL stimulation in control and in 10 mM noradrenaline (top) or 2 mM
baclofen (bottom) in 2.5 mM external calcium and then in 4.5 mM external calcium. Averages normalized to the first EPSC are shown on the right.
Error bars show ± SEM.depletion of releasable vesicles (a process that might have
occurred as we stimulated at regular intervals while we al-
lowed noradrenaline to perfuse onto our slice prepara-
tion). To test this possibility, we applied noradrenaline in
the absence of stimulation of the PB input. We found
that the evoked PB EPSC was immediately blocked
to maximal extent when stimulation recommenced in
noradrenaline (Figure 7D), indicating that activity-driven
depletion was not required for the action of noradrenaline
and suggesting that the release machinery itself is the
likely target of noradrenergic block.
We have shown that noradrenaline reduces transmitter
release at parabrachial terminals in the CeAL by a pre-
synaptic mechanism that does not change release prob-
ability. In contrast, activation of GABAB receptors with
baclofen, which also reduces transmitter release, was
accompanied by a reduction in release probability. What
then is the functional significance of these two different
types of presynaptic modulation? Transmitter release isNegated by a rise in presynaptic calcium and follows a power
relationship so that small changes in calcium are trans-
lated into significantly larger changes in transmitter re-
lease (Dodge and Rahamimoff, 1967). As noradrenaline
reduces transmitter release without changing release
probability, we predicted that conditions that increase re-
lease probability (such as a build up of residual calcium
during trains of action potentials) would be less effective
in relieving inhibition than for inhibitors that lower release
probability, such as baclofen. Two results support this
idea. First, paired-pulse stimulation shows that the ampli-
tude of the second EPSC is greatly enhanced relative to
the first in the presence of baclofen as compared to nor-
adrenaline. Thus, while both baclofen and noradrenaline
reduced the EPSC by a similar extent, facilitation of the
second EPSC was 63% in baclofen as compared to
41% in noradrenaline (Figure 5). Similarly, raising extracel-
lular calcium from 2.5 mM to 4.5 mM in the presence of
noradrenaline (10 mM, Figure 7E, top) increased evokeduron 56, 880–892, December 6, 2007 ª2007 Elsevier Inc. 887
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Noradrenergic Inhibition in the Central AmygdalaEPSC amplitude and reduced PPR similarly to that seen
when raising calcium in the samemanner in control condi-
tions (amplitude: 21.5% ± 9.3% increase in NAd, n = 8, p <
0.05 compared to 28.1% ± 8.3% in control. PPR: 8.1% ±
1.1% in noradrenaline compared with 9.0% ± 3.1% in
control, n = 9 and 8, respectively, ANOVA p > 0.05). In con-
trast, increasing external calcium in the presence of baclo-
fen (2 mM, Figure 7E, bottom) produced a significant
increase in amplitude (42.2% ± 2.7%, n = 4, p < 0.05)
and a larger reduction in PPR than in control or noradren-
aline (26.0% ± 3.1%, n = 4, ANOVA p < 0.05 for both
conditions).
Synaptic Release of Noradrenaline Inhibits
PB Input
The CeAL receives significant noradrenergic innervation
from the nucleus tractus solitarius and the locus coeruleus
(Fallon et al., 1978). To identify the sites of terminations of
these afferents, sections where the PB terminals were la-
beled with DiI were immunostained for the enzyme dopa-
mine-b-hydroxylase (DBH). These DBH-positive fibers
were found in close apposition with the perisomatic PB
terminals (Figure 8A). Histochemical and fiber tracing
studies have shown that noradrenergic fibers enter the
central amygdala via the ventral amygdalofugal pathway
(VAF) and the bed nucleus of the stria terminalis (Fallon
et al., 1978), which is also the pathway for the excitatory
PB input to the CeA (Figure 1C), and where we had posi-
tioned our bipolar stimulating electrode to elicit PB-
EPSCs. Thus, it seems likely that our stimulation paradigm
would also activate noradrenergic afferents into the CeAL.
However, application of the a2-specific antagonist yohim-
bine had no significant effect on the evoked PB-CeAL
EPSC (Figure 3D; 8.8% ± 4.4% decrease, n = 7, p =
0.7), indicating that little or no noradrenaline is released
under our baseline stimulation (up to 0.17 Hz) and record-
ing conditions. To increase noradrenaline release, afferent
fibers were stimulated with short high-frequency trains
(5 stimuli at 50 or 100 Hz). The brief tetanus was followed
with a test stimulus that was compared to a single isolated
stimulus with no preceding train (Figure 8B).We found that
theEPSCevoked100msafter the train of stimuliwas inhib-
ited by 23.8%±2.5% (Figures 8C and 8D; p < 0.01, n = 18),
an effect fully blocked by the a2-adrenoceptor antagonist
yohimbine (Figure 8C; 1.2% ± 1.8% inhibition, p = 0.49,
n = 9). This inhibition was significantly potentiated by
the subsequent application of the selective noradrenaline
uptake inhibitor reboxetine (Figure 8C, 10 mM) to 30.3% ±
3.1% (p < 0.01, n = 9). This action of noradrenaline had
a prolonged time course of action, lasting up to 1 s, and
was potentiated throughout its time course by reboxetine,
consistent with its actions on noradrenaline uptake. At 1 s
after the brief tetanus, noradrenergic inhibition was
4.5% ± 2.0% (p < 0.05, n = 5) under control conditions,
but was greatly enhanced when uptake was subsequently
blocked with reboxetine, increasing to 18.9% ± 4.3%
(Figure 8E; p < 0.05, n = 4).888 Neuron 56, 880–892, December 6, 2007 ª2007 Elsevier IncDISCUSSION
In this studywe have shown that neurons in the lateral sec-
tor of the central amygdala receive a potent excitatory in-
put from the parabrachial nucleus that carries ascending
nociceptive information. Single parabrachial fibers form
large perisomatic synapses that have multiple release
sites and can drive postsynaptic cells to threshold. This
region is also extensively innervated by noradrenergic
afferents (Fallon et al., 1978), and we show that noradren-
aline released by these afferents selectively activates
presynaptic a2 adrenoceptors on parabrachial inputs,
leading to inhibition of transmitter release. This inhibition
requires Gbg subunits that act to reduce the number of
active release sites.
Inhibition of transmitter release by presynaptic autore-
ceptor activation has been recognized for many years.
At mammalian synapses, a range of transmitters acting
at either metabotropic (Miller, 1998) or ionotropic (Mac-
Dermott et al., 1999) receptors can inhibit transmitter re-
lease. Three general mechanisms have been described
to explain these presynaptic actions (Miller, 1998; Wu
and Saggau, 1997). These are (1) inhibition of presynaptic
calcium channels that are responsible for initiating trans-
mitter release; (2) activation of presynaptic ion channels,
typically potassium or chloride channels that effectively
shunt the presynaptic terminal and either reduce calcium
influx or block action potential invasion, and (3) regulation
of the vesicle release complex downstream of calcium in-
flux. Of these, the first twomechanisms both result in a re-
duction of terminal calcium (Dittman and Regehr, 1996;
Wu and Saggau, 1994) and a consequent reduction of
transmitter release by reducing transmitter release proba-
bility (Delaney and Jahr, 2002; Manabe et al., 1993). At
mammalian synapses, the third mechanism has generally
been inferred as a result of changes in the frequency of
spontaneous transmitter release, a process that is inde-
pendent of calcium (Thompson et al., 1993). Moreover,
in cases where such a mechanism has been suggested,
the presynaptic modulator involved (adenosine, GABA)
additionally has actions on presynaptic calcium (Dittman
and Regehr, 1996) and consequent changes in release
probability. Indeed, it has been suggested that while mod-
ulation of the release complexmay play a role, presynaptic
inhibition is largely achieved by changes in calcium influx
(Dittman and Regehr, 1996; Miller, 1998; Wu and Saggau,
1997). We show here that noradrenergic modulation of the
PB inputs to CeAL neurons is entirely due to an effect on
the release complex, with no effect on calcium influx or
release probability.
Adrenergic a2 receptors are G protein-coupled recep-
tors (Hein, 2006). Recent studies have shown that Gbg
can inhibit vesicular release downstream of calcium entry
(Blackmer et al., 2001), possibly by directly binding to
SNAP25 (Blackmer et al., 2005; Chen et al., 2005; Gerach-
shenko et al., 2005). Consistent with these findings, we
show that scavenging Gbg subunits with mSIRK blocks
noradrenergic inhibition at these synapses and that.
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Noradrenergic Inhibition in the Central AmygdalaFigure 8. Endogenously Released Noradrenaline Activates Presynaptic Adrenoceptors to Inhibit Evoked PB-CeAL EPSCs
(A) Fluorescence image (scale bar, 25 mm) showing DiI-labeled PB perisomatic basket terminals (red) and immunolabeled DBH-positive noradrenergic
terminals (green) in CeAL. Inset shows close apposition of DBH-positive terminals and DiI-positive PB terminal at higher magnification (scale bar,
10 mm).
(Bi) Experimental protocol used to detect the activation of adrenoceptors following the endogenous release of noradrenaline stimulated by short high-
frequency trains of stimulation (5 stimuli at 100 Hz) in the medial fiber bundle. The test response is compared to a similar response following a short
high-frequency train of stimulation (the train response is subtracted).
(Bii) Example of PB-CeAL EPSCs stimulated using this protocol, showing the test EPSC following the train (subtracted test stimulus) and the test
EPSC alone (test stimulus only).
(C) Overlaid test responses (indicating the EPSC was preceded by a short high-frequency train) in control, in the presence of the selective noradren-
aline reuptake inhibitor reboxetine (10 mM), and in reboxetine and yohimbine 10 and 20 mM, respectively).
(D) Summary data showing the inhibition of the test response stimulated 100 ms after the brief high-frequency train, in control conditions (p < 0.01,
n = 18), in 10 mM reboxetine (p < 0.01, n = 11), and in 20 mM yohimbine (p = 0.49, n = 9).
(E) Time course for the inhibition of test EPSCs following a short high-frequency stimulus train (5 stimuli at 100 Hz) in control (filled circles) and following
application of reboxetine (unfilled squares). Significance levels are indicated by stars: *p < 0.05, **p < 0.01. n = 5–10 for each time point.reducing the available SNAP-25Gbg-binding sites also re-
duced the effect of noradrenaline. Notably, noradrenergic
inhibition of transmitter release was never complete (Fig-
ure 3). Differential expression of noradrenergic receptors
or the composition of the SNARE complex at individual re-
lease sites on the basket terminal could lead to inhibition
of release from this subset of sites, resulting in a change
in the number of sites contributing to action potential-
driven release, i.e., a change in N. Functionally, such
a mechanism results in presynaptic inhibition that wouldNbe less susceptible to relief by residual calcium building
up in the terminals during repetitive presynaptic activity.
Presynaptic inhibition that reduces release by downregu-
lating calcium influx, such as GABAB-mediated presynap-
tic inhibition (Isaacson, 1998), may result in fewer sites
releasing early in a train of action potentials, but as resid-
ual calcium builds up within the terminals during the train,
all of the release sites could potentially participate in the
action potential-evoked response. In contrast, a mecha-
nism of presynaptic inhibition that reduces the numbereuron 56, 880–892, December 6, 2007 ª2007 Elsevier Inc. 889
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Noradrenergic Inhibition in the Central Amygdalaof release sites available still limits the number of sites that
might participate in transmission regardless of the build up
of residual calcium and increase in release probability.
Synaptically released noradrenaline caused a clear re-
duction in transmitter release by activating a2 adrenore-
ceptors. Neurons in the CeAL also express postsynaptic
calcium-dependent potassium channels that mediate
the slow AHP (Lopez de Armentia and Sah, 2004). As
with many other neurons (Sah, 1996), this slow AHP is
modulated by b adrenoceptors (Lopez de Armentia and
Sah, 2004). Interestingly, synaptically released noradrena-
line, despite having clear effects on presynaptic adreno-
ceptors, had no effect on the slow AHP in these neurons,
even when noradrenaline uptake was blocked with rebox-
etine (A.J.D. and P.S., unpublished data). The reasons for
such an organization are not clear, but these observations
do suggest that synaptically released noradrenaline has
little or no access to postsynaptic b adrenoceptors in
CeAL neurons.
Pain is a conscious experience in which nociceptive in-
puts are integrated with cognitive and emotional factors.
The amygdala plays a key role in assigning affective va-
lence to sensory stimuli (Davis andWhalen, 2001; LeDoux,
2000), and the spino-parabrachio-amygdaloid nocicep-
tive pathway is involved in integrating the autonomic and
emotional aspects of pain (Bernard et al., 1996; Neugeba-
uer et al., 2004). Neurons in the lateral division are inner-
vated by large perisomatic basket terminals from neurons
in the pain-responsive PB (Sarhan et al., 2005). The highly
specialized anatomy of these terminals provides large
suprathreshold excitatory inputs and thus is particularly
well suited to providing a reliable source of ascending no-
ciceptive information to the CeA. Activation of stress/
arousal circuits are well known to lead to increased nor-
adrenaline release in the CeA (Morilak et al., 2005), a struc-
ture that is involved in the generation of stress-induced
analgesia seen in both animals and humans (Bellgowan
and Helmstetter, 1996; Rhudy and Meagher, 2000). Our
results suggest that an important mediator of stress-
induced analgesia could be the potent modulation by




Slices were prepared from 21- to 42-day-old Wistar rats (including
DiI-labeled rats) in accordance within the guidelines of the Institutional
Animal Ethics Committee. Rats were anesthetized using halothane,
decapitated, and their brains removed into ice-cold ACSF solution
containing (in mM) 118 NaCl, 25 NaHCO3, 10 glucose, 2.5 CaCl2, 1.2
NaH2PO4, and 1.3 MgCl2. Brains were sliced into 350 mm thick coronal
sections using a Leica VT1000S vibratome at 0C, transferred to
a chamber containing ACSF at 33C–34C for 30 min, and then main-
tained for several hours in ACSF at room temperature.
Whole-cell recordings were made from brain slices maintained at
32C–33C in a recording chamber continuously perfused with oxy-
genated ACSF and visualized using IR/DIC techniques. Recording
electrodes (3–5 MU) were filled with pipette solution containing (mM)
CsMeSO4 135, NaCl 8, HEPES 10, Mg2ATP 2, and Na3GTP 0.3890 Neuron 56, 880–892, December 6, 2007 ª2007 Elsevier In(pH 7.2 with CsOH, osmolarity 290 mOsm/kg). Whole-cell voltage-
clamp recordings were made using a patch-clamp amplifier (Multi-
clamp 700A, Axon Instruments, Foster City, CA) controlled by an Apple
Macintosh G4 computer. Current signals were filtered at 4–8 kHz and
digitized at 20 kHz (Instrutech ITC18, Greatneck, NY), acquired,
stored, and analyzed on the Macintosh G4 using Axograph software
(Axon Instruments). Access resistance was 5–20 MU and was moni-
tored throughout the experiment. GABAergic transmission was
blocked with picrotoxin (100 mM) and CGP53855A (1 mM) in the exter-
nal solution.
EPSCs were evoked using either a theta glass stimulator placed into
the slice or a concentric bipolar stimulator placed just over the surface
of the slice. Responses shown are averages of 10–50 individual trials.
Student’s t tests were used for statistical comparisons between
groups (except where indicated as otherwise). Results are expressed
as mean ± SEM. Drugs were added to the superfusate, including
(Sigma) picrotoxin and reboxetine and NEM, (Tocris) CGP55845A,
noradrenaline, clonidine, cirazoline, yohimbine, prazosin, isoprenaline,
and NBQX (from calbiochem), mSIRK, and (Alamone) TTX. Slices were
incubated in Pertussis toxin (Sigma-Aldrich) and botulinum toxin A (gift
from Dr Meunier) at 32C.
DiI Labeling
Male Wistar rats (4–5 weeks of age) were anesthetized with a ketamine
(100 mg/kg)/xylazine (20 mg/kg) mixture. After animals were placed in
a stereotaxic frame, an incision was made to expose the skull surface.
A small hole was drilled in the skull, and the underlying dura was re-
moved. A micropipette filled with DiI (Molecular Probes, Eugene, OR)
was lowered into the left parabrachial nucleus (9.0 mm caudal to
bregma; 2.4 mm lateral to midline; 7.3 mm ventral to skull surface). Af-
ter positive pressure was applied to the pipette to deliver 50–100 nl of
DiI, the pipette was left in place for 5min to minimize diffusion of the DiI
back along the injection tract. The pipette was then removed, the hole
sealed with bone wax, and the incision closed with surgical staples. Af-
ter 7 days for transport of DiI, animals were either used for electrophys-
iological recordings as described above, or they were anesthetized
with sodium pentobarbitone (80 mg/kg, i.p.) and perfused transcar-
dially with 2% sodium nitrite solution (in 0.1 M phosphate buffer,
pH 7.4) followed by 500 ml of 4% formaldehyde (in 0.1 M phosphate
buffer, pH 7.4). Brains were then removed, postfixed for 2 hr, and cry-
oprotected overnight in 10% sucrose (in 0.1 M phosphate-buffered
saline [PBS], pH 7.4) at 4C. Serial, coronal forebrain (40 mm), and
brainstem (50 mm) sections were cut using a freezing microtome.
Immunolabeling
Forebrain sections containing the amygdala were washed in PBS,
blocked for 1 hr in 3% BSA, and incubated overnight in mouse anti-
dopamine-b-hydroxylase (1:1000; Chemicon International, USA).
Sections were then washed in PBS before a 2 hr incubation in goat
anti-mouse-Alexa Fluor-488 (1:300, Molecular Probes, Eugene, OR).
Following another PBS wash, all sections were mounted onto subbed
slides and coverslipped with fluorescent mounting medium (DakoCy-
tomation, Denmark). A series of sections through the parabrachial
nucleus were also mounted and coverslipped to allow the placement
of the injection site to be determined.
IR-DIC and low-resolution DiI fluorescence images were captured
from analog video images from aDageMTi IR1000Ex camera attached
to an Olympus BX51WI microscope, using a Lifeview CAPVIEW USB
video capture device. High-resolution images were captured on either
a Zeiss Axioplan-2 fluorescence microscope using Axiovision 3.1
imaging software or on a Zeiss LSM 510 Meta confocal microscope.
Variance Mean Analysis
Given a synaptic connection with N release sites, with an average re-
lease probability of p, the response to stimulation is given by Npq,
where q is the response to a single quantum of transmitter, then the
variance in the amplitude of the evoked synaptic current is given byc.
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When the synapse is stimulated repeatedly, the mean synaptic cur-
rent I is given by I = Npq. Under these conditions, the variance of the
synaptic current s2 is related to the mean current by (Clements,
2003; Silver, 2003)
s2 =qI I2=N: (2)
For synapses with multiple release sites, as in the case of the para-
brachial inputs to CeAL neurons, variability in quantal size between re-
lease sites (intersite variability) and variability at each site (intrasite var-
iability), determined by factors such as vesicle filling and latency of
release, need to be included (Foster and Regehr, 2004). Total variance








where CVQII is the intersite variability andCVQI is the intrasite variability.
For somatic PB synapses, we determined the total quantal variability
(CV2Iq +CV
2
IIq) from quantal events evoked in Sr
2+, and intrasite variabil-
ity was approximated as 0.044 (Foster and Regehr, 2004; Saviane and
Silver, 2006). Electrically evoked EPSCs (50 to 80 episodes) were re-
corded at a range of calcium and magnesium concentrations (from
0.25/4 to 5/1.3 mM [Ca2+]ext/[Mg
2+]ext) in control and in 10 mM nor-
adrenaline. The variance of these responses was plotted against the
mean response amplitude at each calcium/magnesium concentration
to construct individual variance mean plots, and the average variance
and mean for each calcium/magnesium ratio across cells was used to
construct the population variance mean plot. The population variance
mean plot was fit with a parabolic function (Equation 3) to estimate the
parameters q and N.
Calcium Indicator Loading
Membrane-permeant calcium indicators (Magnesium Green-AM and
Oregon Green 488 BAPTA-1 AM, 50 ng; Molecular Probes, Eugene,
OR) were dissolved in 5 ml pluronic acid/DMSO and 45 ml dry DMSO
with vortexing, then diluted to a final concentration with 50 ml filtered
ACSF and sonicated for 15 min. Indicator was applied under low pres-
sure via a low-resistance patch pipette into the ventral-amygdalofugal
fiber bundle in a 350 mm thick coronal slicemaintained at 32C in a per-
fusion chamber oriented to provide solution flow away from the CeAL
(Figure 7A). Loaded slices were incubated for 2–3 hr before calcium
imaging.
Parabrachial Fiber Stimulation and Terminal Calcium
Imaging
Parabrachial fibers were stimulated electrically using a bipolar stimu-
lating electrode placed adjacent to the labeling site. Whole-field fluo-
rescence measurements were recorded using a monochromator-
based imaging system (Polychrome V; T.I.L.L. Photonics, Martinsried,
Germany). Labeled PB terminals were illuminated with 488 nm light
and visualized using a 403 water-immersion objective. Images were
acquired with an in-line transfer, cooled CCD camera (T.I.L.L. Photon-
ics). Images were analyzed off-line using Vision (T.I.L.L Photonics).
Kinetic sequences were then constructed over time for each of the
selected labeled terminals. Calcium signals were measured as the rel-
ative change in fluorescence over baseline fluorescence (DF/F).
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